Home › Therapeutic areas › Immunology › Graves' Disease
Graves' Disease (3 companies)
Companies with an active program in Graves' Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| IMVT | Immunovant | ImmunologyNeurology Rare | 1 | Phase 3 | $6.87B | 4 |
| SEPN | Septerna | ImmunologyMetabolic+1 Rare | 1 | Phase 1 | $1.90B | 5 |
| VRDN | Viridian Therapeutics | ImmunologyOphthalmology | 2 | Approved | $3.41B | 7 |
No companies match.